The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients

NCT ID: NCT04035096

Last Updated: 2019-07-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2022-06-30

Brief Summary

The purpose is to evaluate the effectiveness of high dose intravenous vitamin C (IVC) therapy plus very low carbohydrate diet (VLCD) for stage IV colon cancer (with KRAS and BRAF mutation ) with or without chemotherapy.

Detailed Description

High dose IVC induces pro-oxidant effects, inhibits energy metabolism, acts as cytotoxic effect, and induces cancer cell apoptosis and necrosis. The recent advance in Warburg effect makes a new direction in high dose IVC therapy. The Warburg effect is the enhanced conversion of glucose to lactate observed in tumor cells, even in the presence of normal levels of oxygen. Converting glucose to lactate, rather than metabolizing it through oxidative phosphorylation in the mitochondria, is far less efficient as less ATP is generated per unit of glucose metabolized. Therefore, a high rate of glucose uptake is required to meet increased energy needs to support rapid tumor progression..

Vitamin C shares very similar structure with glucose. The high-dose IVC gets accessibility to glucose transporter, with competition to glucose. Having a reduced level of blood sugar seems to be a necessary parameter to increase IVC's anticancer effectiveness. VLCD with high dose IVC showed effectiveness in case series.

The investigator's project is a single-centered, clinical trial (pilot study) for stage IV colon cancer patients with or without chemotherapy. The experimental group will receive high dose vitamin C 75 or 100g (with blood vitamin C level > 350 mg/dl) in 1000 ml distilled water in 2-hour infusion, twice per week for 12 weeks. Then maintenance dose is 75-100 g once per 2 weeks for 12 weeks. Very low carbohydrate diet will be executed for the first 12 weeks. The control group will be matched for age, sex and chemotherapy and target therapy medication. The control group will receive usual care. The primary outcome will be the response rate by computerized tomography (CT) of the chest, abdomen and pelvis at 12 weeks and 24 weeks. The secondary outcome will be the improvement of tumor markers (CEA and Ca199).

This is the first clinical trial of IVC therapy with VLCD for stage IV colon cancer in Taiwan and in the world. This innovation will give us a primitive answer on the effectiveness of IVC therapy with VLCD for cancers. Vitamin C is a cheap and harmless therapy. The study result will open a door for alternative cancer treatment.

Conditions

Colon Cancer Stage Iv

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

The high-dose vitamin C with very low carbohydrate diet group

1. Initiation of High dose IVC therapy: start with 25g IVC biweekly for one week; 50g IVC biweekly for one week; 75g biweekly for one week.

2. Blood vitamin C level measurement: Confirm the plasma vitamin C level above 350 mg/dl by Arkray company PocketChem VC ( Kyoto, Japan) from the 75g/dose

3. Once the target blood level is confirmed, the dose remains g biweekly for 12 weeks. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level. The blood vitamin C level will be checked again and record. The final dose will be kept for 12 weeks.

4. The Riordan IVC protocol (Taiwan)

5. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks

6. The infusion schedule change within 2 weeks is accepted with the fixed frequency per week or month

7. VLCD intervention in the first 12 weeks

Group Type: EXPERIMENTAL

Ascorbic Acid

Intervention Type: DRUG

1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.

2. The final dose will be kept for 12 weeks.

3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks

The control group

1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs

2. Usual care

Group Type: ACTIVE_COMPARATOR

Control group

Intervention Type: OTHER

1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs

2. Usual care

Interventions

Ascorbic Acid

1. Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.

2. The final dose will be kept for 12 weeks.

3. Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks

Intervention Type: DRUG

Control group

1. Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs

2. Usual care

Intervention Type: OTHER

Other Intervention Names

VLCD (very low carbohydrate diet) intervention in the first 12 weeks

Eligibility Criteria

Inclusion Criteria

• stage IV colon cancer
• with KRAS and BRAF mutation

Exclusion Criteria

• G-6-PD deficiency,
• metastatic kidney disease,
• obstructive uropathy,
• nephrotic syndrome,
• under other alternative medicine treatment or intravenous vitamin treatment,
• pregnant or lactating women,
• impaired renal function with a serum creatinine ≥ 132.6µmol/L(1.5 mg/dL)
• significant fluid retention(pleural effusion, ascites, lower leg edema),
• terminal heart failure,
• incapability to make decision,

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Taiwan University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chin-Ying Chen, MD, MHSc

Role: PRINCIPAL_INVESTIGATOR

Department of Family Medicine, National Taiwan University Hospital

Locations

National Taiwan University Hospital

Taipei, , Taiwan

Countries

Taiwan

Central Contacts

Chin-Ying Chen, MD, MHSc

Role: CONTACT

crystalcychen@ntu.edu.tw

886-2-23123456

Chin-Ying Chen, MD, MHSc

Role: CONTACT

crystalcychen@ntu.edu.tw

886-2-21323456

Facility Contacts

Shyr-Chyr Chen, MD, EMBA

Role: primary

scchen@ntu.edu.tw

886-2-23123456

Other Identifiers

201901083MINB

Identifier Type: -

Identifier Source: org_study_id